{
  "id": "f02863801545ee75",
  "title": "FDA Expands the Indications of 2 Tests to Identify Patients With HER2+ Breast Cancer Eligible for T - DXd",
  "description": "20251216T204500Z",
  "content": "",
  "source": "onclive.com",
  "source_url": "https://www.onclive.com/view/fda-expands-the-indications-of-2-tests-to-identify-patients-with-her2-breast-cancer-eligible-for-t-dxd",
  "published_at": "20251216T204500Z",
  "fetched_at": "2025-12-17T00:22:43.797460+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.onclive.com/view/fda-expands-the-indications-of-2-tests-to-identify-patients-with-her2-breast-cancer-eligible-for-t-dxd",
    "url_mobile": "",
    "title": "FDA Expands the Indications of 2 Tests to Identify Patients With HER2+ Breast Cancer Eligible for T - DXd",
    "seendate": "20251216T204500Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/onclive/30face1978b94f808baa063015a7c536f31f0cf9-1280x720.png",
    "domain": "onclive.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}